Preparation and evaluation of cytotoxic potential of paclitaxel containing poly-3-hydroxybutyrate-co-3-hydroxyvalarate (PTX/PHBV) nanoparticles

• Published in: Brazilian journal of biology Vol. 83; pp. 1 - 7
• Main Authors: Aslam, A., Berger, M. R., Ullah, I., Hameed, A., Masood, F.
• Format: Journal Article
• Language: English; Portuguese
• Published: São Carlos Instituto Internacional de Ecologia 2023
• Subjects: Antitumor agents; Apoptosis; Biocompatibility; BIOLOGY; cancer; Cancer therapies; Chemotherapy; Cytotoxicity; Efficiency; Encapsulation; Immune system; MTT; Nanoparticles; Paclitaxel; Particle size; pH effects; PHBV nanoparticles; Poly-3-hydroxybutyrate; Polyethylene glycol; Polyhydroxybutyric acid; Scanning electron microscopy; Toxicity; paclitaxel; citotoxicidade; PHBV nanoparticles; câncer; cancer; nanopartículas de PHBV; MTT; cytotoxicity
• ISSN: 1519-6984; 1678-4375; 1678-4375
• DOI: 10.1590/1519-6984.275688

Abstract Paclitaxel (PTX) is a potent anticancer drug. In the present study, PTX was loaded in poly-3-hydroxybutyrate-co-3-hydroxyvalarate (PHBV) to fabricate the PTX/PHBV (drug-loaded) nanoparticles via the nanoprecipitation method. Blank PHBV nanoparticles were also prepared. The drug-encapsulation efficiency of PTX/PHBV nanoparticles was 45±0.4%. The PTX/PHBV nanoparticles exhibited a pH-sensitive release profile and followed a quasi-Fickian diffusion mechanism. Cytotoxic properties of PHBV and PTX/PHBV nanoparticles were checked against the MCF-7 and Caco-2 cell lines. The PHBV nanoparticle did not inhibit the proliferation of MCF-7 and Caco-2 cell lines, thus depicting their non-toxic and biocompatible nature. On the other hand, the PTX/PHBV nanoparticles demonstrated 1.03-fold higher cytotoxicity and 1.61-fold enhanced apoptosis after treatment with the PTX/PHBV nanoparticles versus free PTX. In summary, the PHBV nanoparticles could be a potential candidate for the delivery of PTX for cancer treatment. Resumo Paclitaxel (PTX) é um potente medicamento anticancerígeno. No presente estudo, o PTX foi carregado em poli-3-hidroxibutirato-co-3-hidroxivalarato (PHBV) para fabricar as nanopartículas de PTX / PHBV (carregadas com drogas) através do método de nanoprecipitação. Nanopartículas de PHBV em branco também foram preparadas. A eficiência de encapsulamento do fármaco das nanopartículas de PTX/PHBV foi de 45±0,4%. As nanopartículas de PTX/PHBV exibiram um perfil de liberação sensível ao pH e seguiram um mecanismo de difusão quase Fickiano. As propriedades citotóxicas das nanopartículas de PHBV e PTX/PHBV foram verificadas em relação às linhagens celulares MCF-7 e Caco-2. A nanopartícula de PHBV não inibiu a proliferação das linhagens celulares MCF-7 e Caco-2, retratando assim sua natureza atóxica e biocompatível. Por outro lado, as nanopartículas de PTX/PHBV demonstraram citotoxicidade 1,03 vezes maior e apoptose 1,61 vezes maior após tratamento com as nanopartículas de PTX/PHBV versus PTX livre. Em resumo, as nanopartículas de PHBV podem ser candidatas potenciais para a entrega de PTX no tratamento do câncer.